Intellikine has developed a portfolio of novel drug candidates that selectively inhibit the PI3Kδ isoform, the PI3Kγ isoform as well as dual inhibitors that target both PI3Kδ and PI3Kγ for the treatment of hematologic malignancies.
PI3Kδ and PI3Kγ are primarily restricted to cells of hematopoietic origin. Intellikine's PI3Kδ/γ inhibitors have been shown to inhibit cell proliferation and induce apoptosis in patient-derived lymphoma cells and cell lines. In addition, PI3Kδ/γ inhibitors exert indirect effects on the tumor microenvironment, such as survival factor signaling, neo-angiogenesis, motility and cellular infiltration, which may further contribute to efficacy against hematologic malignancies.
Intellikine currently has a portfolio of PI3Kδ/γ-selective inhibitors currently under preclinical evaluation as potential therapies for hematologic malignancies.